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ABSTRACT 
Although iron oxide magnetic nanoparticles (MNP) have been proposed for numerous 
biomedical applications, little is known about their biotransformation and long-term 
toxicity in the body.  Dimercaptosuccinic acid (DMSA)-coated magnetic nanoparticles 
have been proven efficient for in vivo drug delivery, but these results must nonetheless be 
sustained by comprehensive studies of long-term distribution, degradation and toxicity.  We 
studied DMSA-coated magnetic nanoparticles effects in vitro on NCTC 1469 non-
parenchymal hepatocytes, and analyzed their biodistribution and biotransformation in vivo 
in C57BL/6 mice.  Our results indicate that DMSA-coated magnetic nanoparticles have 
little effect on cell viability, oxidative stress, cell cycle or apoptosis on NCTC 1469 cells in 
vitro.  In vivo distribution and transformation was studied by alternating current magnetic 
susceptibility measurements, a technique that permits distinction of MNP from other iron 
species. Our results show that DMSA-coated MNP accumulate in spleen, liver and lung 
tissues for extended periods of time, in which nanoparticles undergo a process of 
conversion from superparamagnetic iron oxide nanoparticles to other non-
superparamagnetic iron forms, with no significant signs of toxicity. 
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1. Introduction 
Nanotechnology is currently an extremely active research area, and new applications are 
continually being developed for use as diagnostic and therapeutic agents [1]. Magnetic 
nanoparticles (MNP) are one of the most widely used nanotechnological tools in 
biomedicine; their nanometric size provides special features that favor the development of 
new applications, and they can be manipulated under the influence of an external magnetic 
field. In recent years, MNP have been proposed for applications such as magnetic 
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resonance imaging (MRI), drug delivery, cell sorting, hyperthermia, nanosensors and tissue 
engineering [2, 3]. The development of new technologies implies the need to determine 
their toxicity and to identify potential risks and side effects that could arise from their use, 
especially important in the case of nanotechnology [4]. 
The toxic potential of nanoparticles is due mainly to their small size.  Nanomaterials 
have a high surface/volume ratio, rendering them very reactive, and allows their 
accumulation within cells or tissues [5, 6]. This reactivity can lead to toxicity due to 
interaction between nanomaterials and biological components [7]. MNP toxicity also 
depends on other factors such as chemical composition, size, shape, surface coating, 
structure, porosity, solubility, surface charge, aggregation and oxidation [8-10]; this makes 
it difficult to draw general conclusions about their safety and biocompatibility. Previous 
studies analyzed in vitro toxicity of several kinds of iron oxide MNP on different cell types, 
with variable results. Whereas some showed that MNP can reduce cell viability, affect cell 
morphology or adhesion, or impair cell metabolism [6, 11-13], others found no significant 
cytotoxic effects [14-16]. These contradictory results are closely related to a concept known 
as "cell vision", refering to the contact point between nanoparticles and cells. Nanoparticles 
reach the plasma membrane of cells, which has a different composition depending on the 
cell type, and determine the "vision" that the cell has for these materials, and the effects that 
nanoparticles exert on the cell [17-20]. For this reason, it is necessary to analyze each 
nanoparticle type on an appropriate cell line. The results of in vitro toxicity tests are not 
sufficient, however, and must be validated in vivo. MNP biodistribution and toxicity in the 
body is the other main concern that arises from the increasingly widespread use of 
nanoparticles for biomedical applications. Several studies in animal models showed 
preferential accumulation of iron oxide MNP in spleen and liver, and to a lesser extent in 
other organs, depending on dosage and surface coating [21-25]. Other research showed that 
iron metabolism biochemical pathways can process iron oxide MNP [26, 27]. In addition to 
initial MNP accumulation, it is therefore important to analyze their temporal biodistribution 
and transformation, as variation in their location could determine changes in potential in 
vivo toxic effects. There is nonetheless little information available from long-term in vivo 
studies of these factors. 
We undertook analysis of in vitro cytotoxicity and long-term in vivo biodistribution and 
toxicity of DMSA-MNP, whose efficiency for in vivo drug delivery has been demonstrated 
[23]. We analyzed the possible cytotoxic effects of DMSA-MNP on NCTC 1469 hepatic 
cells.  As most previous studies of MNP cytotoxicity were conducted at low nanoparticle 
concentrations, or incubation times potentially too short to determine all possible toxic 
effects on cultured cells [28], we used iron concentrations up to 0.5 mg/ml, and incubation 
times up to 72 h. 
The main cause of the toxic effects of MNP is excessive production of ROS (reactive 
oxygen species) [1], which can result in oxidative stress. As nanoparticle-induced oxidative 
stress can have several negative effects on cells, such as alteration of organelle structure, 
decreased cell viability, activation of various cell stress pathways, cell cycle impairment or 
apoptosis induction [29], we studied these processes in a variety of in vitro tests. To 
determine DMSA-MNP biodistribution in vivo, we used alternating current (AC) 
susceptibility measurements, a method utilized to characterize the magnetic properties of 
MNP and to detect them in tissues [30-32]. We present the analysis of DMSA-MNP 
accumulation and biotransformation in various organs for three months after a multiple-
dose treatment in C57BL/6 mice. We also studied DMSA-MNP elimination in feces and 
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MNP toxicity by biochemical analysis of blood and urine. Our results help to determine the 
risks involved in the biomedical use of this type of MNP. 
2. Materials and Methods 
2.1 Synthesis and characterization of magnetic nanoparticles 
DMSA-MNP were synthesized as described [33] with slight modifications.  Briefly, a 
mixture of Fe(acac)3 (20 mmol), 1,2-dodecanediol (100 mmol), oleic acid (60 mmol) and 
oleylamine (60 mmol) in 1-octadecene (200 ml) was introduced in a four-necked flask and 
heated (200ºC, 2 h) with mechanical stirring under N2 flow. The solution was heated to 
reflux (315ºC, 30 min), cooled to room temperature (RT) and washed several times with 
ethanol using a permanent magnet to precipitate the particles and discard the supernatant. 
Nanoparticles were dispersed in toluene, and 80 ml of this suspension, containing 1.8 mmol 
Fe, were added to a solution of DMSA (2 mmol) in dimethyl sulfoxide (20 ml). The 
mixture was stirred mechanically for 48 h. Solvent was discarded, precipitated DMSA-
MNP were washed three times with ethanol and redispersed in water. Finally, pH was 
increased to 10 by adding a NaOH solution, and the resulting homogeneous dispersion was 
dialyzed and filtered through a 0.22 µm pore-size filter before adjusting to pH 7. Iron 
concentration of the dispersion was measured by inductively coupled plasma atomic 
emission spectroscopy (ICP-AES). Transmission electron microscopy (TEM) was 
performed using a 200-KeV JEOL-2000 FXII microscope. MNP size, shape and 
distribution were analyzed from TEM images.  A drop of a dilute magnetic nanoparticle 
suspension was placed on a carbon-coated copper grid and the solvent allowed to evaporate 
at room temperature.  Colloidal characterization was performed by dynamic light scattering 
(DLS) using a ZetaSizer Nano ZS (Malvern). 
2.2 Cell culture 
The murine NCTC 1469 non-parenchymal hepatocyte cell line was cultured in DMEM 
with 10% horse serum, 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM 
L-glutamine in standard culture conditions (37ºC, 5% CO2, 90% relative humidity). 
2.3 Nanoparticle uptake 
For iron uptake and subcellular localization of nanoparticles, cells were preincubated 
with DMSA-MNP (0.5 mg Fe/ml) for 24 h. Cells were then fixed in 2% glutaraldehyde and 
1% tannic acid in HEPES (2 h, RT). Cells were rinsed with HEPES, post-fixed with 1% 
osmium tetroxide (1 h) and 2% uranyl acetate (30 min; both at 4ºC), dehydrated with a 
series of acetone solutions and gradually infiltrated with Epon resin. The resin was allowed 
to polymerize (60ºC, 48 h), and ultrathin sections (60-70 nm) were obtained with a 
diamond knife mounted on a Leica EM UC6 ultramicrotome. Sections were supported on a 
formvar/carbon-coated gold grid and observed using a JEOL-1011 electron microscope 
(acceleration voltage 100 kV). Images were obtained with an Erlangshen ES1000W 
camera. 
2.4 Cell viability assay 
Cell viability was determined by the AlamarBlue assay (Invitrogen). Cells were cultured 
in 24-well plates (104 cells/well; 1 ml complete medium) with various concentrations of 
DMSA-MNP or 100 µM bisphenol A (BPA) in dimethyl sulfoxide (DMSO). AlamarBlue 
reagent was added to each well (100 µl), and incubated (72 h). Fluorescence was evaluated 
at different times in a TECAN Infinite 200 Pro fluorometer (560 nm excitation wavelength, 
590 nm emission wavelength). Cell viability was expressed as the percentage of 
fluorescence of DMSA-MNP-treated or BPA-treated cells compared to untreated cells. 
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2.5 Oxidative stress analysis 
Oxidative stress can be determined indirectly by analyzing reduced glutathione (GSH) 
levels using the GSH-sensitive probe monochlorobimane (mCB). Cells were preincubated 
with various concentrations of DMSA-MNP (24 h) or 750 µM H2O2 (30 min). As mCB can 
be incorporated to other -SH protein groups, we added controls treated with 200 µM 
1-buthionine-(S,R)-sulfoximine (BSO) for 24 h. This treatment depletes cell GSH levels, 
and the appropriate BSO-treated control background signal was subtracted from each 
sample. For the last hour of incubation, 100 µM mCB was added to each sample. 
Fluorescence was analyzed immediately on a TECAN Infinite 200 Pro fluorometer (390 nm 
excitation wavelength, 485 nm emission wavelength). 
2.6 Caspase-3 activity assay 
Apoptosis of NCTC 1469 cells was determined by analysis of cleaved caspase-3 activity 
after incubation with various DMSA-MNP concentrations, 100 µM BPA in DMSO, or 
DMSO alone (72 h). Assays were performed using a fluorometric caspase-3 assay kit 
(Abcam), following manufacturer’s instructions. 
2.7 Western blot 
NCTC 1469 cells, preincubated with various DMSA-MNP concentrations, 750 µM 
H2O2, DMSO, or 100 µM BPA in DMSO for different time, were lysed in lysis buffer (1% 
Triton-X 100, 50 mM Tris, 150 mM NaCl, 5 mM NaF, 1 mM sodium orthovanadate, 1 mM 
PMSF, 1 mM EDTA, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 2 nM okadaic acid)(30 min, 
4ºC). The lysate was clarified by centrifugation and 40 µg of total protein from each 
sample, determined with the Micro BCA protein assay kit (Pierce), were mixed with 
Laemmli sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 30% glycerol, 5% β-
mercaptoethanol, 0.02% bromophenol blue) and loaded on 12% SDS-polyacrylamide gels 
for electrophoresis. Proteins were transferred to a 0.2 µm-pore nitrocellulose membrane 
(BioRad), which was blocked with 5% w/v bovine serum albumin in Tris-buffered saline 
(TBS). For immunoblotting, we used specific primary antibodies for phospho-ERK, ERK, 
phospho-JNK (Thr183/Tyr185), JNK, phospho-p38 MAPK (Thr180/Tyr182), p38 MAPK, 
cleaved caspase-3 (all from Cell Signaling) and β-actin (Sigma). After incubation with 
appropriate horseradish peroxidase-conjugated secondary antibodies (Dako), protein bands 
were visualized using ECL Western Detection Reagent (GE Healthcare) and developed on 
A-Plus Medical film (Konica Minolta). 
2.8 Cell cycle analysis 
For cell cycle analysis, cells were incubated with various DMSA-MNP concentrations or 
100 µM BPA (72 h). Cells were collected by centrifugation, resuspended and incubated in 
ice-cold 70% ethanol (5 min), washed with ice-cold PBS and stained with 20 µg/ml 
propidium iodide and 100 µg/ml ribonuclease (45 min, RT). A total of 104 cells were 
analyzed per experiment. The percentage of cells in each cell cycle phase was determined 
in a GALLIOS flow cytometer (Beckman Coulter) using MultiCycle AV software (Phoenix 
Flow Systems). 
2.9 Mouse model 
Twelve-week-old female C57BL/6 mice (Harlan Laboratories) were maintained in the 
Centro Nacional de Biotecnología (CNB) animal facility. Mice (n = 4/group) received 5 
intravenous (i.v.) injections of phosphate-buffered saline (PBS; control) or DMSA-MNP 
(15 mg Fe/kg/injection) in two weeks. At several times after the last injection, feces and 
urine samples were collected, mice were euthanized and spleen, liver, lungs, kidneys and 
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blood were harvested for analysis. All animal studies were approved by the CNB Ethics 
Committee for Animal Experimentation in compliance with national and European Union 
legislation. 
2.10 Alternating current (AC) magnetic susceptibility measurements 
Murine tissues were freeze-dried overnight and transferred to gelatin capsule sample 
holders for magnetic characterization using a Quantum Design MPMS-XL SQUID 
magnetometer, with AC amplitude of 0.25 mT in a temperature range from 5 to 200 K at 1 
Hz. 
2.11 Prussian blue staining 
After extraction, organs were fixed in 4% paraformaldehyde and embedded in paraffin 
blocks. Sections (7 µm) were deparaffinized and rehydrated before staining. Prussian blue 
staining was performed using equal volumes of 1 N HCl and 10% w/v potassium 
ferrocyanide (15 min) and counterstained with filtered Mayer’s hematoxylin (3 min) and 
eosin (30 sec). Sections were washed in running tap water (10 min), dehydrated and 
mounted with Entellan (Merck). 
2.12 Iron quantification in feces 
Quantitative determination of iron was carried out by ICP-AES analysis. Feces were 
collected and pooled at different times after DMSA-MNP administration. Samples were 
incubated with 65% nitric acid (1 ml, 1 h, 60ºC) and analyzed. The elemental analysis 
determined the total iron content in samples. 
2.13 Blood and urine biochemical analysis 
Blood samples were maintained at room temperature (4 h), centrifuged (100 x g, 30 min) 
and sera collected. An independent laboratory analyzed serum samples for alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, and γ-
glutamyltranspeptidase (GGT). Urine samples were analyzed for glucose, protein, bilirubin, 
urobilinogen, pH and blood using AUTION Sticks 10EA for urine (Arkray). 
2.14 Quantification and statistical analysis 
Gel bands were quantified with ImageJ software (NIH). Data are represented as mean ± 
SD. Statistical analysis was performed using a two-tailed Student’s t test. Data were 
considered significantly different at a value of p <0.05 and highly significant at p <0.01. 
 
3. Results and discussion 
3.1 Nanoparticle synthesis and characterization 
Using established synthesis protocols [33, 34], we obtained uniform monodisperse 
DMSA-MNP with a magnetite core of 9.2 nm ± 13% (Fig. 1A). Some aggregation took 
place when particles were transferred to water, yielding DMSA-MNP suspensions with 
hydrodynamic sizes of ~65 nm (Fig. 1B). The polydispersity index (PDI) was 0.22. We also 
analyzed nanoparticle ζ-potential in a wide pH range (Fig. 1C); these studies are of interest 
as data indicate that particle size and surface charge can influence cell internalization and 
biodistribution of MNP [7, 16]. However, nanoparticle physicochemical properties in a 
physiological medium may vary, due to protein adsorption to nanoparticle surface forming 
the so-called protein corona, which can influence nanoparticle stability, uptake, and toxicity 
[35, 36]. We analyzed the MNP hydrodynamic size in complete culture medium, and size 
variations at different time points up to 72 h (Fig. 1D). The long-term MNP incubation in 
this medium resulted in an increase in the hydrodynamic size to ~170 nm, which 
subsequently decreased during the first 5 hours of incubation to ~85 nm, that remained 
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stable thereafter, probably due to the initial adsoprtion of a large amount of low-affinity 
proteins, which are then replaced by a smaller number of proteins with higher affinity [35]. 
This type of MNP has been used in previous in vitro studies, on several cell lines, showing 
MNP uptake and accumulation in lysosomes [16, 23]. These organelles contain an acid 
medium. Low pH may affect MNP and protein corona surface charge, which could result in 
variations in MNP aggregation state. Therefore, we analyzed the hydrodynamic size in 
complete medium at acidic pH (Fig. 1E). The size reached in this case was similar to that 
obtained for the nanoparticles in complete medium at physiological pH. However, unlike 
what was observed at physiological pH, in this case the hydrodynamic size did not decrease 
over time, but remained around 150 nm, indicating nanoparticle aggregation due to 
decreased stability of the colloidal suspension. 
 
Fig. 1.  Nanoparticle characterization.  (A) Transmission electron micrograph (TEM) of DMSA-MNP.  (B) 
Hydrodynamic diameter of DMSA-MNP determined by dynamic light scattering (DLS). PDI = polydispersity indez. (C) 
Surface charge of DMSA-MNP at various pH, determined by DLS. (D) Hydrodynamic diameter of DMSA-MNP in 
complete culture medium at various incubation times determined by DLS. Data are represented as mean hydrodynamic 
size. The numbers in each time point indicate the PDI. (E) Hydrodynamic diameter of DMSA-MNP in complete culture 
medium at various pH and two incubation times determined by DLS. Data are represented as mea hydrodynamic size, and 
the numbers indicate the PDI. 
 
3.2 NCTC 1469 cell uptake of DMSA-MNP 
Although MNP can affect cell viability even when they are not internalized, most of their 
effects are uptake-dependent and the nature of the effect depends largely on MNP fate 
within the cell [7, 37]; it is thus necessary to determine whether nanoparticles are 
internalized. We analyzed DMSA-MNP internalization by TEM after 24 h incubation. 
TEM images showed that DMSA-MNP entered NCTC 1469 cells and accumulated in large 
double-membrane vesicles distributed in cytoplasm (Fig. 2A). Although nanoparticle-
induced oxidative stress can result in damage to organelles [38], we observed no changes in 
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organelle structure, possibly because MNP remained inside closed vesicles, which could 
prevent toxic effects on cell components. 
 
Fig. 2.  Nanoparticle uptake and cell viability.  (A) Representative TEM of NCTC 1469 cells incubated with 0.5 mg/ml Fe 
(24 h).  (B) AlamarBlue viability assay of NCTC 1469 cells untreated (Ctrl), incubated with various DMSA-MNP 
concentrations or 100 µM BPA (24, 48 or 72 h).  Data were normalized to control cells, and are shown as mean ± SD (n = 
3).  Two-tailed, unpaired Student’s t test, *p <0.05; **p <0.01. 
 
3.3 In vitro DMSA-MNP cytotoxicity 
Most in vitro toxicity assays are based on the use of colorimetric or fluorescent dyes to 
determine cell viability or function. Although these assays are accepted as general toxicity 
detection methods, they might not be completely accurate when testing nanomaterials, due 
to nanoparticle-dye interaction or adsorption, nanoparticle color or autofluorescence [39].  
Nanoparticle toxicity must thus be assessed using specific tests. Here we analyzed cell 
viability, oxidative stress, activation of cell stress pathways, apoptosis and cell cycle to 
determine DMSA-MNP toxicity on NCTC 1469 cells. 
Several previous studies examined the effects of DMSA-MNP on different cell types, 
and showed little reduction in cell viability [11, 16, 40]. These studies used low MNP 
doses, however, or incubation times too short to permit analysis of all possible toxic effects 
of iron oxide nanoparticles. Here we used higher concentrations and longer incubation 
times than usual. We analyzed cell viability using the AlamarBlue assay (Fig. 2B). Cultured 
NCTC 1469 cell viability was slightly affected by DMSA-MNP at all incubation times and 
nanoparticle concentrations tested, whereas exposure of these cells to 100 µM BPA, used as 
a liver toxicity control [41], produced a significant decrease in cell viability. These data 
showed that DMSA-MNP have little toxicity in this cell line, with no notable influence on 
cell proliferation. 
MNP can produce oxidative stress from excessive generation of ROS that exceeds the 
antioxidant capacity of cells. GSH is an antioxidant defense able to neutralize ROS at low 
levels, generating the oxidized form GSSG. When the GSH/GSSG ratio decreases, cells 
activate cell stress responses, which can be protective, inflammatory, or lead to cell death 
[42]. We tested oxidative stress indirectly by GSH detection in NCTC 1469 cells. GSH has 
a critical role in cell defense against oxidizing agents [43], acting as a reducing equivalent 
(H+ + e-) donor. Low GSH levels are associated with oxidative stress, for which they are a 
good marker [44]. One method used to determine GSH levels in living cells is based on the 
GSH-sensitive probe mCB. Glutathione S-transferases form GSH-mCB complexes that can 
be measured fluorometrically [45]. Treatment with various concentrations of DMSA-MNP 
led to a non-significant decrease in GSH levels, whereas 750 µM H2O2 treatment reduced 
GSH to 28% of control levels (Fig. 3A). 
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Cell responses depend on the activation of various signaling pathways. Three such 
pathways, ERK (extracellular signal-regulated kinase), p38 MAPK (mitogen-activated 
protein kinase) and JNK (c-Jun N-terminal kinase) MAPK cascades, have been studied as 
upstream oxidative stress events after cell exposure to nanoparticles [38, 46]. Nanoparticle 
binding to some cell surface receptors can activate these pathways; depending on the 
specific pathway activated, as well as stimulus strength and duration [38], apoptosis 
mediators such as caspases can be activated, or changes induced in cell proliferation. The 
ERK pathway is involved in proliferation, differentiation, development, cell survival and 
tumorigenesis. JNK activation is critical for regulating stress responses and is involved in 
apoptosis, inflammation and tumorigenesis; p38, which is activated by many physical and 
chemical cell stressors, regulates cell motility, inflammation, osmoregulation and apoptosis 
[47]. In Western blot, we analyzed the phosphorylated and unphosphorylated forms of 
ERK, p38 and JNK in NCTC 1469 cells after 24 h treatment with several DMSA-MNP 
concentrations or 30 min treatment with 750 µM H2O2. DMSA-MNP treatment did not 
alter expression either of unphosphorylated forms of the three proteins, or of 
phosphorylated forms of JNK and p38 at any time point (Fig. 3B). ERK phosphorylation 
increased after 0.5 mg/ml DMSA-MNP treatment (24 h), although the phosphorylated 
protein/total protein ratio was not significantly higher compared to controls (Fig. 3C). We 
detected increased ERK, p38 and JNK phosphorylation when cells were incubated with 
H2O2 (Fig. 3B,C), indicating pathway activation, which correlated with reduced GSH levels 
(Fig. 3A). 
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Fig. 3.  Oxidative stress analysis.  (A) Glutathione (GSH) content in NCTC 1469 cells untreated (Ctrl), incubated with 
various DMA-MNP concentrations (24 h) or 750 µM H2O2 (30 min).  Data were normalized to control cells (n = 3). (B) 
Representative images of western blot analysis of stress signaling pathway activation in NCTC 1469 cells untreated 
(control), incubated with DMA-MNP or H2O2 as in (A).  Phosphorylated and total ERK, JNK and p38 were detected as 
stress indexes; β-actin was used as a loading control.  (C) Amounts of phosphorylated and total ERK, JNK and p38 were 
normalized to that of β-actin, represented as x-fold change in the phosphorylated/total protein ratio relative to untreated 
controls (Ctrl).  Data shown as mean ± SD (n = 3). Two-tailed, unpaired Student’s t test, *p <0.05. 
 
Nanoparticle interaction with the cell surface or intracellular MNP accumulation might 
activate other cell responses such as programmed cell death. Apoptosis is produced by the 
activation of caspases, effector proteases involved in proteolytic cascades that lead to cell 
death; these cascades are classified as mitochondrial-dependent or -independent. Both 
routes converge in the activation of caspase-3 [48]. We used two methods to analyze 
caspase-3 activation in NCTC 1469 cells exposed to DMSA-MNP. Apoptotic activity was 
determined using a caspase-3 activity assay. Cells cultured with DMSA-MNP did not show 
increased caspase-3 activity relative to untreated controls, while 100 µM BPA treatment 
increased protease activity >4.5 times (Fig. 4A). We also used immunoblot analysis of 
 10 
cleaved caspase-3. Active caspase-3 was not detectable in samples from cells incubated 
with DMSA-MNP, whereas it was found when cells were treated with 100 µM BPA (Fig. 
4B). Quantification of the protein bands normalized to untreated controls showed results 
similar to those from the caspase-3 activity assay (Fig. 4C). 
 
Fig. 4.  Apoptosis and cell cycle analysis.  (A) Caspase-3 activity assay of NCTC 1469 cells untreated (control), incubated 
with various DMSA-MNP concentrations, 100 µM BPA in dimethyl sulfoxide (DMSO), or DMSO alone (72 h).  Data 
were normalized and represented as x-fold change relative to untreated controls (n = 3).  (B) Representative images of 
western blot analysis of cleaved caspase-3 and β-actin as apoptotic index and loading control, respectively.  (C) The 
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cleaved caspase-3 amount was normalized to that of β-actin and represented as x-fold change relative to untreated controls 
(n = 3).  (D) Representative cell cycle cytometric analysis of NCTC 1469 cells untreated (control), incubated with various 
DMSA-MNP concentrations, or  100 µM BPA (72 h; 104 cells/experiment; n = 2).  Data are shown as mean ± SD.  Two-
tailed, unpaired Student’s t test, **p <0.01. 
 
Nanoparticles also affect cell cycle progression [5, 6], which is closely related to cell 
uptake of MNP [49]. Cytometric analysis of the cell cycle showed that 100 µM BPA led to 
an increase in the sub-G1 population (>40%) and a decrease in G0-G1 (∼30%) and S 
(∼10%) populations compared to untreated controls (Fig. 4D). DMSA-MNP slightly 
affected the NCTC 1469 cell cycle after 72 h treatment, with a maximum 6.8% increase in 
the sub-G1 population at 0.5 mg/ml (Fig. 4D). 
3.4 Biodistribution and biotransformation of DMSA-MNP in murine tissues 
To study DMSA-MNP in murine tissues after multiple dose i.v. administration, we used 
AC magnetic susceptibility measurements. The out-of-phase susceptibility (χ”(T)) profile is 
especially useful for detecting superparamagnetic material in tissue samples, since other 
iron-containing species such as paramagnetic deoxyhemoglobin or diamagnetic 
oxyhemoglobin do not contribute to χ”(T). Moreover, MNP can be distinguished from 
other superparamagnetic biogenic species such as ferritin, based on differences in the 
temperature position of their χ”(T) maxima [50, 51]. 
The magnetic behavior of DMSA-MNP has been characterized [32]. Before degradation, 
the magnetic susceptibility of DMSA-MNP shows a single peak in both in- and out-of-
phase components, indicative of blocking of particle magnetic moments. In samples at a 
distinct particle concentration, susceptibility peak location on the temperature axis changes 
due to variations in dipolar interactions produced by the distinct MNP aggregation levels. 
The χ”(T) peak is located at ~65K for the most aggregated samples, and at ~40K for the 
most dilute, in which dipolar interactions are negligible [32]. In addition to changes in the 
degree of MNP aggregation, particle size change is another source of variation in shape and 
location of the MNP χ”(T) peak at different temperature, such that a size reduction shifts 
the χ”(T) maximum towards temperatures lower than 40K for the type of DMSA-MNP 
used here [32]. 
In our experiments, blood, spleen, liver, kidney, heart and lung tissues were 
magnetically characterized to track MNP accumulation and degradation for 3 months post-
nanoparticle administration. We found minimal or no χ”(T) signal in blood, heart and 
kidney tissues (not shown), whereas the χ”(T) component of the magnetic susceptibility of 
all spleen, liver and lung tissues showed a single peak in the temperature range observed for 
similar DMSA-MNP in earlier studies [32], confirming the presence of MNP in the tissues; 
controls (PBS-treated mice) showed no peak (Fig. 5A). The highest χ”(T) signal, found in 
spleen and liver samples, was one order of magnitude greater than that for lung.  Over the 
3-month period after nanoparticle administration, the maximum χ”(T) for each tissue 
decreased systematically. The χ”(T) peak also shifted towards lower temperatures with 
time, clearly observed when χ”(T) data are normalized to the maximum (Fig. 5B). The 
results indicate a degradation process over the 3-month period, possibly due to nanoparticle 
disaggregation, reduction in nanoparticle size, or both. The position of the χ”(T) peak on 
the temperature axis for liver samples at 3 months post-DMSA-MNP administration was 
~30K. As this temperature is lower than the that of the χ”(T) peak for diluted DMSA-MNP 
samples in conditions of negligible dipolar interactions [32], this displacement cannot be 
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explained only by disaggregation; nanoparticle size appears to be altered, alone or 
accompanied by nanoparticle disaggregation. In spleen and lung tissues, the χ”(T) peak at 
the lowest temperature is ~40K, rendering it rather difficult to estimate the fractions of the 
total number of particles that suffered disaggregation or particle size reduction. 
 
Fig. 5.  Temperature dependence of the out-of-phase component of the AC magnetic susceptibility of murine tissues from 
phosphate-buffered saline (PBS)- (control) or DMSA-MNP-treated mice at different times post-administration (A) as 
obtained from the SQUID magnetometer, and (B) scaled to their maxima. 
 
The height of the χ”(T) peak, when plotted per mass of sample, is proportional to 
particle quantity in tissue [32]. At short times post-injection, as nanoparticles have not yet 
begun to degrade, MNP dispersions in agar can be used as calibration standards to quantify 
particle quantity in tissues [32, 51]. In this study, as aggregation and particle size change 
over time, we have no appropriate standards for precise magnetic quantification. 
Qualitative information can nonetheless be obtained from the relative height of the χ”(T) 
peak at different time points. We observed a clear trend in liver, lung and spleen samples, 
as peak height tended to decrease with time after DMSA-MNP administration. At 3 months 
post-particle administration, we found approximately half the nanoparticle quantity 
observed immediately after administration. The spleen showed three times fewer 
nanoparticles at 3 months post-administration compared to week one after MNP injection. 
The greatest reduction was found in lungs, in which nanoparticle quantities decreased 
approximately six fold. 
AC magnetic susceptibility results were complemented with Prussian blue staining of 
lung, liver and spleen sections, which showed iron agglomeration from 30 min to 3 months 
after i.v. administration of DMSA-MNP (Fig. 6). Lung and liver showed a reduction in 
number of iron clumps, but liver sections also showed an increase in the size of iron 
deposits over time, which might be explained by the formation of phagocytic cell clusters 
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in the liver parenchyma [52]. Spleen sections showed stained areas in the red pulp, even in 
control tissues, possibly due to storage of iron degradation products as a result of 
erythrocyte phagocytosis and the presence of metallophilic macrophages [53]. Although the 
superparamagnetic signal observed by AC susceptibility measurement diminished over 
time in spleen, this decrease was not clearly visible in Prussian blue-stained spleen sections. 
This implies that MNP were transformed to other non-superparamagnetic iron forms that 
can be processed and partially removed by iron metabolic pathways. In contrast to results 
from studies in which other DMSA-coated nanoparticles were used [25], we observed no 
DMSA-MNP in kidney, which might be due to differences in the animal model and/or 
physical characteristics of the nanoparticles. In addition, biodistribution might depend not 
only on the physicochemical properties of this type of nanoparticle, but also on extrinsic 
factors such as MNP dose and the type of anesthetic used [54]. Apart from this iron 
accumulation, we found no structural or histopathological changes in any of the tissues. 
 
Fig. 6.  Prussian blue staining of tissue sections from PBS- (control) or DMSA-MNP-treated mice at different times post-
administration.  Representative images of 15 tissue sections.   Bar: 100 µm. 
 
3.5 MNP elimination 
Although there are some previous studies of in vivo MNP distribution and clearance [21, 
52, 55, 56], little is known of the route of nanoparticle elimination. Very small amounts of 
iron are typically lost from normal hepatocytes. In iron overload situations, however, bile 
can be an important iron excretory pathway [57]. To determine whether this was the case 
after DMSA-MNP administration and accumulation in liver tissue, we analyzed feces iron 
content by ICP-AES for a 3-month period post-DMSA-MNP injection, and found increased 
iron content in feces from day 7 to day 30 (Fig. 7A). We also analyzed feces samples with 
high iron content by AC magnetic susceptibility measurements, and found no 
superparamagnetic signal related to the presence of MNP (not shown). This is consistent 
with the MNP transformation observed in tissues, in which superparamagnetic material is 
biotransformed to other iron forms and can thus be eliminated. 
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Fig. 7.  Excretion and in vivo toxicity of DMSA-MNP.  (A) ICP-AES analysis of iron content in pooled feces from PBS- 
(control) or DMSA-MNP-treated mice at different times post-administration.  (B) Body weights of PBS- (control) or 
DMSA-MNP-treated mice were monitored over a 3-month period after treatment.  Data are shown as mean ± SD (n = 4).  
(C) Biochemistry of blood samples collected from one mouse each from the PBS- (control) or DMSA-MNP-treated 
groups at different times post-administration.  Serum concentrations of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), γ-glutamyltranspeptidase (GGT) and creatinine were analyzed. 
 
3.6 In vivo toxic effects of DMSA-MNP 
One of the main needs for these in vivo studies is to test for possible toxic effects 
resulting from nanoparticle administration, whether due to initial accumulation or to 
subsequent biotransformation processes. Mouse body weight, monitored over a 3-month 
period after DMSA-MNP administration, showed no obvious changes (Fig. 7B).  
Macroscopic and histopathological examination of all tissues harvested at several times 
after the final injection yielded no signs of tissue damage (see Fig. 6). 
As we observed increased quantities of MNP in liver and spleen at 3 months after the 
last DMSA-MNP injection, we tested serum and urine for signs of in vivo toxicity.  
Analysis of serum from DMSA-MNP-injected mice compared to controls showed transient 
increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT), 
enzymes associated mainly with hepatic damage, with a peak at 1 month post-treatment.  
We found transient increases in γ-glutamyltranspeptidase (GGT) and creatinine levels 7 
days after the last DMSA-MNP injection (Fig. 7C). These increases did not compromise 
mouse survival, and the levels detected were within the range of normal values for female 
C57BL/6 mice, considering age and the blood extraction method [58, 59]. Biochemical 
analysis of urine showed normal results at all times for all parameters analyzed (Table 1). 
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Table 1.  Urine biochemical analysis results for PBS-  (control) and DMSA-MNP-treated 
mice 
 Time post-DMSA-MNP administration (days) 
 Control 0 7 30 60 90 
Glucose - - - - - - 
Protein ± ± ± ± ± ± 
Bilirubin - - - - - - 
Urobilinogen - - - - - - 
pH 6 6 5-6 6 5-6 6 
Blood - - - - - - 
 
Notes: Analysis performed using reactive test strips for urine (n = 4). 
Symbols: -, negative; ±, 15 mg/dl. 
 
4. Conclusions 
We studied DMSA-MNP biocompatibility in vitro, and long-term biodistribution and 
clearance in vivo. At the concentrations studied (up to 0.5 mg/ml), the particles produced no 
significant effects on viability, oxidative stress, apoptosis or cell cycle of NCTC 1469 
murine non-parenchymal hepatocytes. The in vivo analyses indicate continuous 
biotransformation of MNP in liver and spleen. Although some signs of acute toxicity were 
found one month post-administration, these were transient and did not compromise mouse 
survival. The results confirm the promise of DMSA-MNP for clinical use. 
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